Search

Your search keyword '"Cicin, I."' showing total 293 results
Start Over Author "Cicin, I."
293 results on '"Cicin, I."'

1. Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series

Author

Cosar R, Sut N, Ozen A, Tastekin E, Topaloglu S, Cicin I, Nurlu D, Ozler T, Demir S, Yıldız G, Şenödeyici E, and Uzal MC

Subjects
breast cancer, her2 enriched subgroup, triple negative breast cancer, subgroup in breast cancer, luminal-b breast cancer, luminal-a breast cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Rusen Cosar,1 Necdet Sut,2 Alaattin Ozen,3 Ebru Tastekin,4 Sernaz Topaloglu,5 Irfan Cicin,5 Dilek Nurlu,1 Talar Ozler,1 Seda Demir,1 Gokay Yıldız,1 Eylül Şenödeyici,6 Mustafa Cem Uzal7 1Department of Radiation Oncology, Trakya University Faculty of Medicine, Edirne, Turkey; 2Department of Biostatistics and Medical Informatics Trakya University Medical Faculty, Edirne, Turkey; 3Department of Radiation Oncology, Eskisehir University Faculty of Medicine, Eskisehir, Turkey; 4Department of Pathology, Trakya University Faculty of Medicine, Edirne, Turkey; 5Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey; 6Trakya University Faculty of Medicine, Edirne, Turkey; 7Department of Radiation Oncology, Istanbul Arel University Faculty of Medicine, Istanbul, TurkeyCorrespondence: Rusen Cosar, Trakya University, Faculty of Medicine, Department of Radiation Oncology, Edirne, Turkey, Tel +902842361074, Email rusencosar@trakya.edu.trPurpose: Many studies report the triple negative breast cancer (TNBC) as the worst subgroup, as such patients do not benefit from anti-hormonal therapy and human epidermal growth factor receptor 2 (HER2) antagonists. While HER2 overexpression was a poor prognostic factor in breast cancer before trastuzumab (Herceptin) was available, TNBC is often reported as the worst BC subgroup since targeted therapy is currently not possible. Since the patience-specific experiences and the current literature did not always align, we aimed to determine the BC subgroup with the shortest survival in our center.Methods: The records of patients with BC who were admitted to Trakya University Faculty of Medicine Department of Medical and Radiation Oncology between July 1999 and December 2019 were reviewed. Patients were divided into four main groups (Luminal A, Luminal B, TNBC, and HER2-enriched) according to the St Gallen International Consensus Panel and four subgroups in accordance with estrogen receptor, progestin receptor and HER2 positivity. Patient characteristics, treatment characteristics and clinical outcomes of the four main subgroups were evaluated. Survival curves were generated using the Kaplan–Meier method, and the significance of survival differences among the selected variables was compared by using the Log rank test. Factors affecting disease-free survival (DFS) and overall survival (OS) were analyzed by Cox regression analysis.Results: Statistical analysis was performed on 2017 patients, after excluding patients with phyllodes tumor, carcinoma-in-situ and missing information from a total of 2474 patients with BC. There were 952 (47.1%) patients in the Luminal A group, 236 (34.1%) in the Luminal B group, 236 (11.7%) in the TNBC group and 142 (7.1%) patients in the HER2 enriched group. HER2-enriched patients had the shortest survival (p < 0.001), with 113.70 ± 7.17 months of DFS and 125.45 ± 3.03 months of OS. For patients who received Herceptin, DFS was 101.50 ± 6.4 months and OS was 118.14 ± 6.16. Patients who did not receive Herceptin had 92.79 ± 18 months of DFS and 94.44 ± 15.23 months of OS.Conclusion: The HER2-enriched subgroup had the worst prognosis despite receiving targeted therapy. While the duration of DFS and OS had no significant difference between TNBC and Luminal A-B subgroups, HER2 enriched subgroup had significantly shorter survival when compared to any other subgroup. HER2-enriched subgroup had a 10-fold greater risk of death compared to the Luminal A subgroup.Keywords: breast cancer, HER2 enriched subgroup, triple negative breast cancer, subgroup in breast cancer, Luminal-B breast cancer, Luminal-A breast cancer

Published
2022

3. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Bachelot, T., Bouzid, K., Campone, M., Desmoulins, I., Coudert, B., Bondarenko, I., Nowecki, Z., Glogowska, I., Ciruelos Gil, E., Errihani, H., Dalenc, F., Ricci, F., Dieras, V., Kaufman, B., Paluch-Shimon, S., Wardley, A., Schneeweiss, A., Ferreira, A., Mano, M., Kalofonos, H., Andreetta, C., Puglisi, F., Montemurro, F., Barrett, S., Zhang, Q., Mavroudis, D., Matus, J., Villarreal Garza, C., Beato, C., Ismael, G., Hu, X., Abdel Azeem, H., Gaafar, R., Perrin, C., Kerbrat, P., Ettl, J., Paepke, S., Hitre, E., Lang, I., Trudeau, M., Verma, S., Li, H., Hoffmann, O., Aktas, B., Cariello, A., Cruciani, G., Tienghi, A., Tondini, C., Al-Twegieri, T., Loman, N., Laing, R., Miles, D., Brain, E., Fasching, P., Lux, M., Frassoldati, A., Aziz, Z., Salas, J., Streb, J., Krzemieniecki, K., Wronski, A., Garcia Garcia, J., Menjon Beltran, S., Cicin, I., Schmid, P., Gallagher, C., Turner, N., Tong, Z., Boer, K., Juhász, B., Horvath, Z., Bianchini, G., Gianni, L., Curigliano, G., Juarez Ramiro, A., Susnjar, S., Matos, E., Sevillano, E., Garcia Estevez, L., Gokmen, E., Uslu, R., Wildiers, H., Schutz, F., Cruz, M., Bourgeois, H., von Schumann, R., Stemmer, S., Dominguez, A., Morales-Vásques, F., Wojtukiewicz, M., Trifunovic, J., Echarri Gonzalez, M.J., Illarramendi Mañas, J., Martinez De Dueñas, E., Voitko, N., Hicks, J., Waters, S., Barrett-Lee, P., Wheatley, D., De Boer, R., Cocquyt, V., Jerusalem, G., Barrios, C., Panasci, L., Mattson, J., Tanner, M., Gozy, M., Vasilopoulos, G., Papandreou, C., Revesz, J., Battelli, N., Benedetti, G., Latini, L., Gridelli, C., Lazaro Leon, J., Alarcón Company, J., Arance Fernandez, A., Barnadas Molins, A., Calvo Plaza, I., Bratos, R., Gonzalez Martin, A., Izarzugaza Peron, Y., Klint, L., Kovalev, A., McCarthy, N., Yeo, B., Kee, D., Thomson, J., White, S., Greil, R., Wang, S., Artignan, X., Juhasz-Böess, I., Rody, A., Ngan, R., Dourleshter, F., Goldberg, H., Doni, L., Di Costanzo, F., Ferraù, F., Drobniene, M., Aleknavicius, E., Rashid, K., Costa, L., de la Cruz Merino, L., Garcia Saenz, J., López, R., Del Val Munoz, O., Ozyilkan, O., Azribi, F., Jaafar, H., Baird, R., Verrill, M., Beith, J., Petzer, A., Moreira de Andrade, J., Bernstein, V., Macpherson, N., Rayson, D., Saad Eldin, I., Achille, M., Augereau, P., Müller, V., Rasco, A., Evron, E., Katz, D., Berardi, R., Cascinu, S., De Censi, A., Gennari, A., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Van den Bosch, J., Kukulska, M., Kalinka, E., Alonso, J., Dalmau Portulas, E., Del Mar Gordon Santiago, M., Pelaez Fernandez, I., Aksoy, S., Altundag, K., Senol Coskun, H., Bozcuk, H., Shparyk, Y., Barraclough, L., Levitt, N., Panwar, U., Kelly, S., Rigg, A., Varughese, M., Castillo, C., Fein, L., Malik, L., Stuart-Harris, R., Singer, C., Stoeger, H., Samonigg, H., Feng, J., Cedeño, M., Ruohola, J., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Grischke, E.-M., Simon, E., Wagner, S., Koumakis, G., Papazisis, K., Ben Baruch, N., Fried, G., Geffen, D., Karminsky, N., Peretz, T., Cavanna, L., Pedrazzioli, P., Grasso, D., Ruggeri, E., D’Auria, G., Moscetti, L., Juozaityte, E., Rodriguez Cid, J., Roerdink, H., Siddiqi, N., Passos Coelho, J., Arcediano Del Amo, A., Garcia Garre, E., García Gonzalez, M., Garcia-Palomo Perez, A., Herenandez Perez, C., Lopez Alvarez, P., Lopez De Ceballos, M.H., Martínez Jañez, N., Mele Olive, M., McAdam, K., Perren, T., Dunn, G., Humphreys, A., Taylor, W., Vera, R., Kaen, L., Andel, J., Steger, G., De Grève, J., Huizing, M., Hegg, R., Joy, A., Kuruvilla, P., Sehdev, S., Smiljanic, S., Kütner, R., Alexandre, J., Grosjean, J., Laplaige, P., Largillier, R., Maes, P., Martin, P., Pottier, V., Christensen, B., Khandan, F., Lück, H.-J., Zahm, D.-M., Fountzilas, G., Karavasilis, V., Safra, T., Inbar, M., Ryvo, L., Bonetti, A., Seles, E., Giacobino, A., Chavarri Guerra, Y., de Jongh, F., van der Velden, A., van Warmerdam, L., Vrijaldenhoven, S., Smorenburg, C.H., Cavero, M., Andres Conejero, R., Oltra Ferrando, A., Redondo Sanchez, A., Ribelles Entrena, N., Saura Grau, S., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Butt, M., Joffe, J., Poole, C., Woodings, P., Chakraborti, P., Yordi, G., Woodward, N., Nobre, A., Luiz Amorim, G., Califaretti, N., Fox, S., Robidoux, A., Li, E., Li, N., Jiang, J., Soria, T., Padrik, P., Lahdenpera, O., Barletta, H., Dohollou, N., Genet, D., Prulhiere, K., Coeffic, D., Facchini, T., Vieillot, S., Catala, S., Teixeira, L., Hesse, T., Kühn, T., Ober, A., Repp, R., Schröder, W., Pectasides, D., Bodoky, G., Kahan, Z., Jiveliouk, I., Rosengarten, O., Rossi, V., Alabiso, O., Pérez Martínez, M., van de Wouw, A.J., Smok-Kalwat, J., Damasecno, M., Augusto, I., Sousa, G., Saadein, A., Abdelhafiez, N., Abulkhair, O., Antón Torres, A., Corbellas Aparicio, M., Llorente Domenech, R., Florián Jerico, J., Garcia Mata, J., Gil Raga, M., Galan Brotons, A., Llombart Cussac, A., Llorca Ferrandiz, C., Martinez Del Prado, P., Olier Garate, C., Rodriguez Sanchez, C., Sanchez Gomez, R., Santisteban Eslava, M., Soberino, J., Vidal Losada Garcia, M., Soto de Prado, D., Torrego Garcia, J., Vicente Rubio, E., Garcia, M., Murias Rosales, A., Granstam Björneklett, H., Narbe, U., Jafri, M., Rea, D., Newby, J., Jones, A., Westwell, S., Ring, A., Alonso, I., Rodríguez, R., Ciruelos, E., Peretz-Yablonski, T., Merot, J.-L., Trask, P., du Toit, Y., Pena-Murillo, C., Revelant, V., and Klingbiel, D.

Published
2021
Full Text
View/download PDF

4. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Author

Zhang, Q., Xu, B., Shao, Z., Wang, X., Geng, C., Yan, X., Tong, Z., Shen, K., Yin, Y., Sun, T., Yang, J., Feng, J., Yan, M., Wang, Y., Liu, Q., Zhang, S., De Laurentiis, M., Santoro, A., Guarneri, V., Colleoni, M., Natoli, C., Cortesi, L., Placido, S., Gianni, L., Ferrau, F., Livi, L., Zambelli, A., Del Mastro, L., Tonini, G., Montemurro, F., Bianchi, G., Pedersini, R., Prete, S., Allegrini, G., Naso, G., Vici, P., Loirat, D., Mailliez, A., Priou, F., Tredan, O., Dalenc, F., Perrin, C., Gligorov, J., Timar David, M., Dohollou, N., Teixeira, L., Brocard, F., Arnaud, A., Delaloge, S., Spano, J.-P., Mansi, L., Andrade, L., Damian, F., Pedrini, J., Aleixo, S., Hegg, R., Junior, R., Reinisch, M., Schmidt, M., Wenzel, C., Grischke, E.-M., Schneeweiss, A., Just, M., Harbeck, N., Schumacher, C., Peters, U., Fischer, D., Forstbauer, H., Liersch, R., Warner, E., Bouganim, N., Doyle, C., Price Hiller, J., Vandenberg, T., Pavic, M., Robinson, A., Roldan Urgoiti, G., Califaretti, N., Alacacioglu, A., Gumus, M., Yalcin, B., Cicin, I., Kose, F., Uygun, K., Kaplan, M., Cubukcu, E., Wardley, A., Harries, M., Miles, D., Doval, D., Gupta, S., Mohapatra, P., Chatterjee, S., Ghadyalpatil, N., Singhal, M., Nag, S., Agarwal, A., Wolf, I., Gal Yam, E., Yerushalmi, R., Peretz, T., Fried, G., Ben Baruch, N., Katz, D., Hamilton, E., Kayali, F., Brufsky, A., Telli, M., Wright, G., Oyola, R., Rakowski, T., Graff, S., Tjulandin, S., Semiglazov, V., Aparicio, A., Ruiz Borrego, M., Merino, L., Guerra Martinez, J., Lopez, E., Yamashita, T., Ohtani, S., Inoue, K., Ito, Y., Niikura, N., Nakayama, T., Sagara, Y., Yanagita, Y., Kamada, Y., Kaneko, K., Kaen, D., Nervo, A., Eniu, A., Schenker, M., Priester, P., Melichar, B., Zimovjanova, M., Sormova, P., Sufliarsky, J., Kakalejcik, M., Belbaraka, R., Errihani, H., Le Than, D., Pham, D., Aravantinos, G., Papadimitriou, C., Koumakis, G., Papandreou, C., Podolski, P., Tabane, K., André, F., Cameron, D., Barrios, C., Patel, S., Patre, M., Morales, L., Patel, S.L., Kaul, M., Barata, T., and O’Shaughnessy, J.

Published
2021
Full Text
View/download PDF

6. LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study

Author

Reinmuth, N., primary, Özgüroğlu, M., additional, Leighl, N.B., additional, Galetta, D., additional, Hacibekiroglu, I., additional, Roubec, J., additional, Sendur, M.A.N., additional, Bria, E., additional, Cicin, I., additional, Grohé, C., additional, Harputluoglu, H., additional, Kilickap, S., additional, Novello, S., additional, Opalka, P., additional, Riccardi, F., additional, Ruseva, R.K., additional, Lang, S., additional, Hodari, M., additional, Donner, N., additional, and de Marinis, F., additional

Published
2023
Full Text
View/download PDF

7. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

Author

Esin, Ece, Oksuzoglu, B., Bilici, A., Cicin, I., Kostek, O., Kaplan, M. A., Aksoy, S., Aktas, B. Y., Ozdemir, O., Alacacioglu, A., Cabuk, D., Sumbul, A. T., Sakin, A., Paydas, S., Yetisir, E., Er, O., Korkmaz, T., Yildirim, N., Sakalar, T., Demir, H., Artac, M., Karaagac, M., Harputluoglu, H., Bilen, E., Erdur, E., Degirmencioglu, S., Aliyev, A., Cil, T., Olgun, P., Basaran, G., Gumusay, O., Demir, A., Tanrikulu, E., Yumuk, P. F., Imamoglu, Inanc, Oyan, B., Cetin, B., Haksoyler, V., Karadurmus, N., Erturk, I., Evrensel, T., Yilmaz, H., Beypinar, I., Kocer, M., Pilanci, K. N., Seker, M., Urun, Y., Yildirim, N., Eren, T., Demirci, U., and Turkish Oncology Group

Published
2019
Full Text
View/download PDF

8. P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes

Author

Johnston, S., primary, Toi, M., additional, O’Shaughnessy, J., additional, Rastogi, P., additional, Campone, M., additional, Neven, P., additional, Huang, C.S., additional, Huober, J., additional, Jaliffe, G. Garnica, additional, Cicin, I., additional, Tolaney, S., additional, Goetz, M.P., additional, Rugo, H., additional, Senkus, E., additional, Testa, L., additional, Del Mastro, L., additional, Shimizu, C., additional, Wei, R., additional, Shahir, A., additional, Munoz, M., additional, Antonio, B. San, additional, Andre, V., additional, Harbeck, N., additional, and Martín, M., additional

Published
2023
Full Text
View/download PDF

9. 10MO EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% — 3-year update

Author

Kilickap, S., primary, Özgüroğlu, M., additional, Sezer, A., additional, Gumus, M., additional, Bondarenko, I., additional, Gogishvili, M., additional, Türk, H.M., additional, Cicin, I., additional, Bentsion, D., additional, Gladkov, O.A., additional, Clingan, P., additional, Sriuranpong, V., additional, He, X., additional, Pouliot, J-F., additional, Seebach, F., additional, Lowy, I., additional, Gullo, G., additional, and Rietschel, P., additional

Published
2023
Full Text
View/download PDF

10. OA01.05 Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression + Chemotherapy: EMPOWER-Lung 1

Author

Garassino, M.C., primary, Kilickap, S., additional, Özgüroğlu, M., additional, Sezer, A., additional, Gumus, M., additional, Bondarenko, I., additional, Gogishvili, M., additional, Nechaeva, M., additional, Schenker, M., additional, Cicin, I., additional, Fuang, H.G., additional, Kulyaba, Y., additional, Dvorkin, M., additional, Zyuhal, K., additional, Scheusan, R.-I., additional, He, X., additional, Kaul, M., additional, Okoye, E., additional, Li, Y., additional, Li, S., additional, Pouliot, J.-F., additional, Seebach, F., additional, Lowy, I., additional, Gullo, G., additional, and Rietschel, P., additional

Published
2023
Full Text
View/download PDF

11. 181P SELECT: A phase II randomized trial evaluating 2 doses of vopratelimab (V) + pimivalimab (P) vs P in TISvopra selected patients (pts)

Author

Gumus, M., primary, Sukalinskaya, A., additional, Andric, Z.G., additional, Cheshuk, V., additional, Ciuleanu, T-E., additional, Sezgin Goksu, S., additional, Cil, T., additional, Cicin, I., additional, Bulat, I.V., additional, Ostapenko, Y.V., additional, Penkov, K.D., additional, Hart, C., additional, Lai, M., additional, Chaao, B., additional, Jimenez, J., additional, Sepahi, A., additional, Shi, G., additional, Trott, S., additional, and Hooper, E., additional

Published
2022
Full Text
View/download PDF

12. LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)

Author

Cho, B.C., primary, Ahn, M-J., additional, Kang, J.H., additional, Soo, R., additional, Baisamut (Reungwetwattana), T., additional, Yang, J.C-H., additional, Cicin, I., additional, Kim, D-W., additional, Wu, Y-L., additional, Lu, S., additional, Lee, K., additional, Pang, Y-K., additional, Zimina, A., additional, Fong, C.H., additional, Poddubskaya, E., additional, Kim, Y., additional, An, T., additional, Lee, H., additional, Byun, H., additional, and Zaric, B., additional

Published
2022
Full Text
View/download PDF

13. 327P Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial

Author

Ho, G.F., primary, Ozguroglu, M., additional, Kilickap, S., additional, Sezer, A., additional, Gumus, M., additional, Bondarenko, I., additional, Gogishvili, M., additional, Nechaeva, M., additional, Schenker, M., additional, Cicin, I., additional, Kulyaba, Y., additional, Dvorkin, M., additional, Zyuhal, K., additional, Scheusan, R.I., additional, Li, S., additional, Pouliot, J-F., additional, Seebach, F., additional, Lowy, I., additional, Gullo, G., additional, and Rietschel, P., additional

Published
2022
Full Text
View/download PDF

14. LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

Author

Özgüroğlu, M., primary, Kilickap, S., additional, Sezer, A., additional, Gumus, M., additional, Bondarenko, I., additional, Gogishvili, M., additional, Nechaeva, M., additional, Schenker, M., additional, Cicin, I., additional, Ho, G.F., additional, Kulyaba, Y., additional, Dvorkin, M., additional, Zyuhal, K., additional, Scheusan, R.I., additional, Li, S., additional, Pouliot, J-F., additional, Seebach, F., additional, Lowy, I., additional, Gullo, G., additional, and Rietschel, P., additional

Published
2022
Full Text
View/download PDF

15. OA11.06 Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1

Author

Kilickap, S., Sezer, A., Özgüroğlu, M., Gumus, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Cicin, I., Fuang, H.G., Kulyaba, Y., Zyuhal, K., Scheusan, R.-I., Baramidze, A., Garassino, M.C., Li, Y., Jia, X., Kaul, M., Perez, J., Seebach, F., Lowy, I., Pouliot, J.-F., Kim, E., Rietschel, P., and Magnan, H.

Published
2024
Full Text
View/download PDF

16. First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis

Author

Isikdogan, A., Sakin, A., Tural, D., Cubukcu, E., Bozkurt, O., Harputluoglu, H., Kefeli, U., Alacacioglu, A., Geredeli, C., Cicin, I., Artac, M., Karabulut, B., Sendur, M., Bilir, C., Turk, H., YALÇIN, SIDDIKA SONGÜL, GÜMÜŞ, MAHMUT, Karadurmus, N., Arslan, C., Cevik, D., Dane, F., Cil, T., and KÖKER, İBRAHİM HAKKI

Subjects
Onco-colon Turkey study subgroup analysis-, ANNALS OF ONCOLOGY, cilt.33, 2022 [Isikdogan A., Turk H., Bilir C., Sendur M., Karabulut B., Artac M., Cicin I., Geredeli C., Alacacioglu A., Kefeli U., et al., -First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer]
Published
2022

17. MO31-2 Telisotuzumab vedotin monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer

Author

Horinouchi, Hidehito, primary, Goldman, J.W., additional, Moiseenko, F., additional, Cicin, I., additional, Filippova, E., additional, Bar, J., additional, Tomasini, P., additional, Ocampo, C., additional, Sullivan, D., additional, Maag, D., additional, Motwani, M., additional, Jin, J., additional, and Camidge, D.R., additional

Published
2022
Full Text
View/download PDF

18. P-90 First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis

Author

Isıkdogan, A., primary, Turk, H., additional, Bilir, C., additional, Şendur, M., additional, Karabulut, B., additional, Artac, M., additional, Cicin, I., additional, Geredeli, C., additional, Alacacioglu, A., additional, Kefeli, U., additional, Harputluoglu, H., additional, Bozkurt, O., additional, Cubukcu, E., additional, Tural, D., additional, Sakin, A., additional, Cil, T., additional, Dane, F., additional, Çevik, D., additional, Arslan, Ç., additional, Karadurmus, N., additional, Gumus, M., additional, and Yalcin, S., additional

Published
2022
Full Text
View/download PDF

19. 63P Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2- high-risk early breast cancer

Author

Paluch-Shimon, S., primary, Neven, P., additional, Huober, J., additional, Cicin, I., additional, Jiang, Z., additional, Goetz, M.P., additional, Shimizu, C., additional, Huang, C., additional, Wei, R.J., additional, Nabinger, S.C., additional, Forrester, T., additional, and Harbeck, N., additional

Published
2022
Full Text
View/download PDF

20. 6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up

Author

Rodriguez Abreu, D., primary, Reck, M., additional, Şendur, N., additional, Park, K., additional, Lee, D.H., additional, Cicin, I., additional, Yumuk, P.F., additional, Orlandi, F.J., additional, Leal, T.A., additional, Soparattanapaisarn, N., additional, Langleben, A., additional, Califano, R., additional, Medgyasszay, B., additional, Hsia, T-C., additional, Otterson, G.A., additional, Woods, T., additional, Jensen, E., additional, Samkari, A., additional, and Boyer, M., additional

Published
2022
Full Text
View/download PDF

21. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Author

Harbeck, N., primary, Rastogi, P., additional, Martin, M., additional, Tolaney, S.M., additional, Shao, Z.M., additional, Fasching, P.A., additional, Huang, C.S., additional, Jaliffe, G.G., additional, Tryakin, A., additional, Goetz, M.P., additional, Rugo, H.S., additional, Senkus, E., additional, Testa, L., additional, Andersson, M., additional, Tamura, K., additional, Del Mastro, L., additional, Steger, G.G., additional, Kreipe, H., additional, Hegg, R., additional, Sohn, J., additional, Guarneri, V., additional, Cortés, J., additional, Hamilton, E., additional, André, V., additional, Wei, R., additional, Barriga, S., additional, Sherwood, S., additional, Forrester, T., additional, Munoz, M., additional, Shahir, A., additional, San Antonio, B., additional, Nabinger, S.C., additional, Toi, M., additional, Johnston, S.R.D., additional, O’Shaughnessy, J., additional, Jimenez, M.M., additional, Johnston, S., additional, Boyle, F., additional, Neven, P., additional, Jiang, Z., additional, Campone, M., additional, Huober, J., additional, Shimizu, C., additional, Cicin, I., additional, Wardley, A., additional, Abuin, G.G., additional, Zarba, J., additional, Lim, E., additional, Sant, P., additional, Liao, N., additional, Christiansen, B., additional, Eigeliene, N., additional, Martin-Babau, J., additional, Ettl, J., additional, Mavroudis, D., additional, Chiu, J., additional, Boer, K., additional, Nagarkar, R., additional, Paluch-Shimon, S., additional, Moscetti, L., additional, Sagara, Y., additional, Kim, S.-B., additional, Maciel, M.M., additional, Tjan-Heijnen, V., additional, Broom, R., additional, Lacko, A., additional, Schenker, M., additional, Volkov, N., additional, Sim Yap, Y., additional, Coccia-Portugal, M., additional, Ángel García Sáenz, J., additional, Andersson, A., additional, Chao, T.-Y., additional, Gokmen, E., additional, Harputluoglu, H., additional, Berzoy, O., additional, Patt, D., additional, McArthur, H., additional, Chew, H., additional, Chalasani, P., additional, Kaufman, P., additional, Tedesco, K., additional, and Graff, S.L., additional

Published
2021
Full Text
View/download PDF

22. Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Author

Clingan, P., Rietschel, P., Gladkov, O., Sriuranpong, V., Gullo, G., Lowy, I., Seebach, F., Lee, S., Pouliot, J., Mcginniss, J., Rizvi, N., Bondarenko, I., Sezer, A., Kilickap, S., GÜMÜŞ, MAHMUT, ÖZGÜROĞLU, Mustafa, Gogishvili, M., Turk, H. M., Cicin, I., and Bentsion, D.

Subjects
Subgroup Analysis from EMPOWER-Lung 1-, JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.10, 2021 [Bondarenko I., Sezer A., Kilickap S., GÜMÜŞ M., ÖZGÜROĞLU M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC]
Published
2021

24. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Miles, D., primary, Ciruelos, E., additional, Schneeweiss, A., additional, Puglisi, F., additional, Peretz-Yablonski, T., additional, Campone, M., additional, Bondarenko, I., additional, Nowecki, Z., additional, Errihani, H., additional, Paluch-Shimon, S., additional, Wardley, A., additional, Merot, J.-L., additional, Trask, P., additional, du Toit, Y., additional, Pena-Murillo, C., additional, Revelant, V., additional, Klingbiel, D., additional, Bachelot, T., additional, Bouzid, K., additional, Desmoulins, I., additional, Coudert, B., additional, Glogowska, I., additional, Ciruelos Gil, E., additional, Dalenc, F., additional, Ricci, F., additional, Dieras, V., additional, Kaufman, B., additional, Ferreira, A., additional, Mano, M., additional, Kalofonos, H., additional, Andreetta, C., additional, Montemurro, F., additional, Barrett, S., additional, Zhang, Q., additional, Mavroudis, D., additional, Matus, J., additional, Villarreal Garza, C., additional, Beato, C., additional, Ismael, G., additional, Hu, X., additional, Abdel Azeem, H., additional, Gaafar, R., additional, Perrin, C., additional, Kerbrat, P., additional, Ettl, J., additional, Paepke, S., additional, Hitre, E., additional, Lang, I., additional, Trudeau, M., additional, Verma, S., additional, Li, H., additional, Hoffmann, O., additional, Aktas, B., additional, Cariello, A., additional, Cruciani, G., additional, Tienghi, A., additional, Tondini, C., additional, Al-Twegieri, T., additional, Loman, N., additional, Laing, R., additional, Miles, D., additional, Brain, E., additional, Fasching, P., additional, Lux, M., additional, Frassoldati, A., additional, Aziz, Z., additional, Salas, J., additional, Streb, J., additional, Krzemieniecki, K., additional, Wronski, A., additional, Garcia Garcia, J., additional, Menjon Beltran, S., additional, Cicin, I., additional, Schmid, P., additional, Gallagher, C., additional, Turner, N., additional, Tong, Z., additional, Boer, K., additional, Juhász, B., additional, Horvath, Z., additional, Bianchini, G., additional, Gianni, L., additional, Curigliano, G., additional, Juarez Ramiro, A., additional, Susnjar, S., additional, Matos, E., additional, Sevillano, E., additional, Garcia Estevez, L., additional, Gokmen, E., additional, Uslu, R., additional, Wildiers, H., additional, Schutz, F., additional, Cruz, M., additional, Bourgeois, H., additional, von Schumann, R., additional, Stemmer, S., additional, Dominguez, A., additional, Morales-Vásques, F., additional, Wojtukiewicz, M., additional, Trifunovic, J., additional, Echarri Gonzalez, M.J., additional, Illarramendi Mañas, J., additional, Martinez De Dueñas, E., additional, Voitko, N., additional, Hicks, J., additional, Waters, S., additional, Barrett-Lee, P., additional, Wheatley, D., additional, De Boer, R., additional, Cocquyt, V., additional, Jerusalem, G., additional, Barrios, C., additional, Panasci, L., additional, Mattson, J., additional, Tanner, M., additional, Gozy, M., additional, Vasilopoulos, G., additional, Papandreou, C., additional, Revesz, J., additional, Battelli, N., additional, Benedetti, G., additional, Latini, L., additional, Gridelli, C., additional, Lazaro Leon, J., additional, Alarcón Company, J., additional, Arance Fernandez, A., additional, Barnadas Molins, A., additional, Calvo Plaza, I., additional, Bratos, R., additional, Gonzalez Martin, A., additional, Izarzugaza Peron, Y., additional, Klint, L., additional, Kovalev, A., additional, McCarthy, N., additional, Yeo, B., additional, Kee, D., additional, Thomson, J., additional, White, S., additional, Greil, R., additional, Wang, S., additional, Artignan, X., additional, Juhasz-Böess, I., additional, Rody, A., additional, Ngan, R., additional, Dourleshter, F., additional, Goldberg, H., additional, Doni, L., additional, Di Costanzo, F., additional, Ferraù, F., additional, Drobniene, M., additional, Aleknavicius, E., additional, Rashid, K., additional, Costa, L., additional, de la Cruz Merino, L., additional, Garcia Saenz, J., additional, López, R., additional, Del Val Munoz, O., additional, Ozyilkan, O., additional, Azribi, F., additional, Jaafar, H., additional, Baird, R., additional, Verrill, M., additional, Beith, J., additional, Petzer, A., additional, Moreira de Andrade, J., additional, Bernstein, V., additional, Macpherson, N., additional, Rayson, D., additional, Saad Eldin, I., additional, Achille, M., additional, Augereau, P., additional, Müller, V., additional, Rasco, A., additional, Evron, E., additional, Katz, D., additional, Berardi, R., additional, Cascinu, S., additional, De Censi, A., additional, Gennari, A., additional, El-Saghir, N., additional, Ghosn, M., additional, Oosterkamp, H.M., additional, Van den Bosch, J., additional, Kukulska, M., additional, Kalinka, E., additional, Alonso, J., additional, Dalmau Portulas, E., additional, Del Mar Gordon Santiago, M., additional, Pelaez Fernandez, I., additional, Aksoy, S., additional, Altundag, K., additional, Senol Coskun, H., additional, Bozcuk, H., additional, Shparyk, Y., additional, Barraclough, L., additional, Levitt, N., additional, Panwar, U., additional, Kelly, S., additional, Rigg, A., additional, Varughese, M., additional, Castillo, C., additional, Fein, L., additional, Malik, L., additional, Stuart-Harris, R., additional, Singer, C., additional, Stoeger, H., additional, Samonigg, H., additional, Feng, J., additional, Cedeño, M., additional, Ruohola, J., additional, Berdah, J.-F., additional, Goncalves, A., additional, Orfeuvre, H., additional, Grischke, E.-M., additional, Simon, E., additional, Wagner, S., additional, Koumakis, G., additional, Papazisis, K., additional, Ben Baruch, N., additional, Fried, G., additional, Geffen, D., additional, Karminsky, N., additional, Peretz, T., additional, Cavanna, L., additional, Pedrazzioli, P., additional, Grasso, D., additional, Ruggeri, E., additional, D’Auria, G., additional, Moscetti, L., additional, Juozaityte, E., additional, Rodriguez Cid, J., additional, Roerdink, H., additional, Siddiqi, N., additional, Passos Coelho, J., additional, Arcediano Del Amo, A., additional, Garcia Garre, E., additional, García Gonzalez, M., additional, Garcia-Palomo Perez, A., additional, Herenandez Perez, C., additional, Lopez Alvarez, P., additional, Lopez De Ceballos, M.H., additional, Martínez Jañez, N., additional, Mele Olive, M., additional, McAdam, K., additional, Perren, T., additional, Dunn, G., additional, Humphreys, A., additional, Taylor, W., additional, Vera, R., additional, Kaen, L., additional, Andel, J., additional, Steger, G., additional, De Grève, J., additional, Huizing, M., additional, Hegg, R., additional, Joy, A., additional, Kuruvilla, P., additional, Sehdev, S., additional, Smiljanic, S., additional, Kütner, R., additional, Alexandre, J., additional, Grosjean, J., additional, Laplaige, P., additional, Largillier, R., additional, Maes, P., additional, Martin, P., additional, Pottier, V., additional, Christensen, B., additional, Khandan, F., additional, Lück, H.-J., additional, Zahm, D.-M., additional, Fountzilas, G., additional, Karavasilis, V., additional, Safra, T., additional, Inbar, M., additional, Ryvo, L., additional, Bonetti, A., additional, Seles, E., additional, Giacobino, A., additional, Chavarri Guerra, Y., additional, de Jongh, F., additional, van der Velden, A., additional, van Warmerdam, L., additional, Vrijaldenhoven, S., additional, Smorenburg, C.H., additional, Cavero, M., additional, Andres Conejero, R., additional, Oltra Ferrando, A., additional, Redondo Sanchez, A., additional, Ribelles Entrena, N., additional, Saura Grau, S., additional, Viñas Vilaro, G., additional, Bachmeier, K., additional, Beresford, M., additional, Butt, M., additional, Joffe, J., additional, Poole, C., additional, Woodings, P., additional, Chakraborti, P., additional, Yordi, G., additional, Woodward, N., additional, Nobre, A., additional, Luiz Amorim, G., additional, Califaretti, N., additional, Fox, S., additional, Robidoux, A., additional, Li, E., additional, Li, N., additional, Jiang, J., additional, Soria, T., additional, Padrik, P., additional, Lahdenpera, O., additional, Barletta, H., additional, Dohollou, N., additional, Genet, D., additional, Prulhiere, K., additional, Coeffic, D., additional, Facchini, T., additional, Vieillot, S., additional, Catala, S., additional, Teixeira, L., additional, Hesse, T., additional, Kühn, T., additional, Ober, A., additional, Repp, R., additional, Schröder, W., additional, Pectasides, D., additional, Bodoky, G., additional, Kahan, Z., additional, Jiveliouk, I., additional, Rosengarten, O., additional, Rossi, V., additional, Alabiso, O., additional, Pérez Martínez, M., additional, van de Wouw, A.J., additional, Smok-Kalwat, J., additional, Damasecno, M., additional, Augusto, I., additional, Sousa, G., additional, Saadein, A., additional, Abdelhafiez, N., additional, Abulkhair, O., additional, Antón Torres, A., additional, Corbellas Aparicio, M., additional, Llorente Domenech, R., additional, Florián Jerico, J., additional, Garcia Mata, J., additional, Gil Raga, M., additional, Galan Brotons, A., additional, Llombart Cussac, A., additional, Llorca Ferrandiz, C., additional, Martinez Del Prado, P., additional, Olier Garate, C., additional, Rodriguez Sanchez, C., additional, Sanchez Gomez, R., additional, Santisteban Eslava, M., additional, Soberino, J., additional, Vidal Losada Garcia, M., additional, Soto de Prado, D., additional, Torrego Garcia, J., additional, Vicente Rubio, E., additional, Garcia, M., additional, Murias Rosales, A., additional, Granstam Björneklett, H., additional, Narbe, U., additional, Jafri, M., additional, Rea, D., additional, Newby, J., additional, Jones, A., additional, Westwell, S., additional, Ring, A., additional, Alonso, I., additional, and Rodríguez, R., additional

Published
2021
Full Text
View/download PDF

25. FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Author

Bondarenko, I., primary, Sezer, A., additional, Kilickap, S., additional, Gümüş, M., additional, Özgüroğlu, M., additional, Gogishvili, M., additional, Turk, H.M., additional, Cicin, I., additional, Bentsion, D., additional, Gladkov, O., additional, Clingan, P., additional, Sriuranpong, V., additional, Rizvi, N., additional, Mcginniss, J., additional, Pouliot, J., additional, Lee, S., additional, Seebach, F., additional, Lowy, I., additional, Gullo, G., additional, and Rietschel, P., additional

Published
2021
Full Text
View/download PDF

26. P47.03 Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2

Author

Goldman, J., primary, Moiseenko, F., additional, Cicin, I., additional, Horinouchi, H., additional, Filippova, E., additional, Bar, J., additional, Lu, S., additional, Tomasini, P., additional, Ocampo, C., additional, Sullivan, D., additional, Maag, D., additional, Motwani, M., additional, Jin, J., additional, and Camidge, D.R., additional

Published
2021
Full Text
View/download PDF

28. Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

Author

Kilickap, S., Sezer, A., Gumus, M., Bondarenko, I., Ozguroglu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Li, S., Lee, S., Makharadze, T., Paydas, S., Nechaeva, M., Seebach, F., Weinreich, D. M., Yancopoulos, G. D., Gullo, G., Lowy, I., Rietschel, P., and TÜRK, HACI MEHMET

Subjects
Kilickap S., Sezer A., Gumus M., Bondarenko I., Ozguroglu M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC-, JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.3, 2021
Published
2021

29. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Author

Miles, D., primary, Gligorov, J., additional, André, F., additional, Cameron, D., additional, Schneeweiss, A., additional, Barrios, C., additional, Xu, B., additional, Wardley, A., additional, Kaen, D., additional, Andrade, L., additional, Semiglazov, V., additional, Reinisch, M., additional, Patel, S., additional, Patre, M., additional, Morales, L., additional, Patel, S.L., additional, Kaul, M., additional, Barata, T., additional, O’Shaughnessy, J., additional, Zhang, Q., additional, Shao, Z., additional, Wang, X., additional, Geng, C., additional, Yan, X., additional, Tong, Z., additional, Shen, K., additional, Yin, Y., additional, Sun, T., additional, Yang, J., additional, Feng, J., additional, Yan, M., additional, Wang, Y., additional, Liu, Q., additional, Zhang, S., additional, De Laurentiis, M., additional, Santoro, A., additional, Guarneri, V., additional, Colleoni, M., additional, Natoli, C., additional, Cortesi, L., additional, Placido, S., additional, Gianni, L., additional, Ferrau, F., additional, Livi, L., additional, Zambelli, A., additional, Del Mastro, L., additional, Tonini, G., additional, Montemurro, F., additional, Bianchi, G., additional, Pedersini, R., additional, Prete, S., additional, Allegrini, G., additional, Naso, G., additional, Vici, P., additional, Loirat, D., additional, Mailliez, A., additional, Priou, F., additional, Tredan, O., additional, Dalenc, F., additional, Perrin, C., additional, Timar David, M., additional, Dohollou, N., additional, Teixeira, L., additional, Brocard, F., additional, Arnaud, A., additional, Delaloge, S., additional, Spano, J.-P., additional, Mansi, L., additional, Damian, F., additional, Pedrini, J., additional, Aleixo, S., additional, Hegg, R., additional, Junior, R., additional, Schmidt, M., additional, Wenzel, C., additional, Grischke, E.-M., additional, Just, M., additional, Harbeck, N., additional, Schumacher, C., additional, Peters, U., additional, Fischer, D., additional, Forstbauer, H., additional, Liersch, R., additional, Warner, E., additional, Bouganim, N., additional, Doyle, C., additional, Price Hiller, J., additional, Vandenberg, T., additional, Pavic, M., additional, Robinson, A., additional, Roldan Urgoiti, G., additional, Califaretti, N., additional, Alacacioglu, A., additional, Gumus, M., additional, Yalcin, B., additional, Cicin, I., additional, Kose, F., additional, Uygun, K., additional, Kaplan, M., additional, Cubukcu, E., additional, Harries, M., additional, Miles, D., additional, Doval, D., additional, Gupta, S., additional, Mohapatra, P., additional, Chatterjee, S., additional, Ghadyalpatil, N., additional, Singhal, M., additional, Nag, S., additional, Agarwal, A., additional, Wolf, I., additional, Gal Yam, E., additional, Yerushalmi, R., additional, Peretz, T., additional, Fried, G., additional, Ben Baruch, N., additional, Katz, D., additional, Hamilton, E., additional, Kayali, F., additional, Brufsky, A., additional, Telli, M., additional, Wright, G., additional, Oyola, R., additional, Rakowski, T., additional, Graff, S., additional, Tjulandin, S., additional, Aparicio, A., additional, Ruiz Borrego, M., additional, Merino, L., additional, Guerra Martinez, J., additional, Lopez, E., additional, Yamashita, T., additional, Ohtani, S., additional, Inoue, K., additional, Ito, Y., additional, Niikura, N., additional, Nakayama, T., additional, Sagara, Y., additional, Yanagita, Y., additional, Kamada, Y., additional, Kaneko, K., additional, Nervo, A., additional, Eniu, A., additional, Schenker, M., additional, Priester, P., additional, Melichar, B., additional, Zimovjanova, M., additional, Sormova, P., additional, Sufliarsky, J., additional, Kakalejcik, M., additional, Belbaraka, R., additional, Errihani, H., additional, Le Than, D., additional, Pham, D., additional, Aravantinos, G., additional, Papadimitriou, C., additional, Koumakis, G., additional, Papandreou, C., additional, Podolski, P., additional, and Tabane, K., additional

Published
2021
Full Text
View/download PDF

30. Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study

Author

Arslan, C., Kefeli, U., Yildirim, E., Isikdogan, A., Karadurmus, N., Karabulut, B., and Cicin, I.

Abstract

23rd ESMO World Congress on Gastrointestinal Cance -- JUN 30-JUL 03, 2021 -- ELECTR NETWORK, [No Abstract Available], ESMO, Amgen Pharmaceuticals, This project was funded by Amgen Pharmaceuticals.

Published
2021

34. 97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

Author

Robinson, A.G., primary, Vicente, D., additional, Tafreshi, A., additional, Parra, H. Soto, additional, Mazieres, J., additional, Cicin, I., additional, Medgyasszay, B., additional, Rodríguez-Cid, J., additional, Okamoto, I., additional, Lee, S., additional, Ramlau, R., additional, Vladimirov, V., additional, Cheng, Y., additional, Halmos, B., additional, Liu, C-C., additional, Schwarzenberger, P., additional, Piperdi, B., additional, and Paz-Ares, L., additional

Published
2021
Full Text
View/download PDF

35. P84.03 GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

Author

Peled, N., primary, Gillis, R., additional, Kilickap, S., additional, Froesch, P., additional, Orlov, S., additional, Filippova, E., additional, Demirci, U., additional, Christopoulos, P., additional, Cicin, I., additional, Bugdayci Basal, F., additional, Yilmaz, C., additional, Fedor, M., additional, Korkmaz, T., additional, Paydas, S., additional, Gautschi, O., additional, Zirtiloglu, A., additional, Eralp, Y., additional, Cinkir, H.Y., additional, Sezer, A., additional, Erman, M., additional, Tural, D., additional, Turna, H.Z., additional, Mazieres, J., additional, Dudnik, E., additional, Reguart, N., additional, Camidge, R., additional, Ng, T.L., additional, Senler, F. Cay, additional, Beypınar, İ., additional, Yazılıtaş, D., additional, Demirkazik, A., additional, Karaoğlu, A., additional, Okutur, K., additional, Şenol Coşkun, H., additional, Nahit Şendur, M.A., additional, Isikdogan, A., additional, Cabuk, D., additional, Yumuk, P.F., additional, Yıldız, I., additional, Kaplan, M.A., additional, Özyılkan, Ö., additional, Öztop, İ., additional, Olmez, O.F., additional, Aydin, K., additional, Aydıner, A., additional, Meydan, N., additional, Grinberg, R., additional, and Roisman, L., additional

Published
2021
Full Text
View/download PDF

36. PS01.09 Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598

Author

Boyer, M., primary, Sendur, M.A.N., additional, Rodríguez-Abreu, D., additional, Park, K., additional, Lee, D.H., additional, Cicin, I., additional, Yumuk, P.F., additional, Orlandi, F., additional, Leal, T., additional, Molinier, O., additional, Soparattanapaisam, N., additional, Langleben, A., additional, Califano, R., additional, Medgyasszay, B., additional, Hsia, T., additional, Otterson, G., additional, Xu, L., additional, Piperdi, B., additional, Samkari, A., additional, and Reck, M., additional

Published
2021
Full Text
View/download PDF

37. FP14.12 Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK–Positive NSCLC Patients: eXalt3.

Author

Selvaggi, G., primary, Wu, Y., additional, Wang, Z., additional, Wu, G., additional, Poddubskaya, E., additional, Reck, M., additional, Mok, T., additional, Chiappori, A., additional, Lee, D.H., additional, Breder, V., additional, Orlov, S., additional, Cicin, I., additional, Cheng, Y., additional, Liu, Y., additional, Fan, Y., additional, Zhou, J., additional, Liang, C., additional, Mao, L., additional, Horn, L., additional, and Wakelee, H.A., additional

Published
2021
Full Text
View/download PDF

38. OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

Author

Kilickap, S., primary, Sezer, A., additional, Gümüş, M., additional, Bondarenko, I., additional, Özgüroğlu, M., additional, Gogishvili, M., additional, Turk, H.M., additional, Cicin, I., additional, Bentsion, D., additional, Gladkov, O., additional, Clingan, P., additional, Sriuranpong, V., additional, Rizvi, N., additional, Li, S., additional, Lee, S., additional, Makharadze, T., additional, Paydas, S., additional, Nechaeva, M., additional, Seebach, F., additional, Weinreich, D.M., additional, Yancopoulos, G.D., additional, Gullo, G., additional, Lowy, I., additional, and Rietschel, P., additional

Published
2021
Full Text
View/download PDF

39. EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%

Author

Sezer, A., Kilickap, S., Gumus, M., Bondarenko, I., ÖZGÜROĞLU, Mustafa, Gogishvili, M., TÜRK, HACI MEHMET, Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Li, S., Lee, S., Gullo, G., Lowy, I., Rietschel, P., and TÜRK, HACI MEHMET

Subjects
=+50%25-%2C+ESMO+Virtual+Congress%2C+ELECTR+NETWORK%2C+19+Eylül+-+18+Ekim+2020%2C+cilt%2E31+[Sezer+A%2E%2C+Kilickap+S%2E%2C+Gumus+M%2E%2C+Bondarenko+I%2E%2C+ÖZGÜROĞLU+M%2E%2C+Gogishvili+M%2E%2C+TÜRK+H%2E+M%2E+%2C+Cicin+I%2E%2C+Bentsion+D%2E%2C+Gladkov+O%2E%2C+et+al%2E%2C+-EMPOWER-Lung+1]%22">Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%-, ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31 [Sezer A., Kilickap S., Gumus M., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., TÜRK H. M. , Cicin I., Bentsion D., Gladkov O., et al., -EMPOWER-Lung 1]
Published
2020

40. patients with advanced hepatocellular carcinoma: A real life data of

Author

Hacioglu, MB, Kostek, O, Karabulut, S, Tastekin, D, Goksu, SS, Alandag, C, Akagunduz, B, Bilgetekin, I, Caner, B, Sahin, AB, Yildiz, B, Kose, F, Kaplan, MA, Gulmez, A, Dogan, E, Guven, DC, Gurbuz, M, Ergun, Y, Karaagac, M, Demiray, AG, Turker, S, Sakalar, T, Ozkul, O, Telli, TA, Sahin, S, Kilickap, S, Bilici, A, Erdogan, B, and Cicin, I

Subjects
hepatocellular carcinoma, regorafenib, disease control rate, overall, survival, chemotherapy, anti-VEGF therapy
Abstract

Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting. Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a secondor third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included. Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (p(PFS)=0.22 and p(OS)=0.85). Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib. C1 [Hacioglu, Muhammet Bekir; Kostek, Osman; Erdogan, Bulent; Cicin, Irfan] Trakya Univ, Dept Med Oncol, Med Fac, Edirne, Turkey. [Karabulut, Senem; Tastekin, Didem] Istanbul Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey. [Goksu, Sema Sezgin] Akdeniz Univ, Med Fac, Dept Med Oncol, Antalya, Turkey. [Alandag, Celal] Karadeniz Tech Univ, Med Fac, Dept Med Oncol, Trabzon, Turkey. [Akagunduz, Baran] Dokuz Eylul Univ, Med Fac, Dept Med Oncol, Izmir, Turkey. [Bilgetekin, Irem] Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Dept Med Oncol, Ankara, Turkey. [Caner, Burcu; Sahin, Ahmet Bilgehan] Uludag Univ, Med Fac, Dept Med Oncol, Bursa, Turkey. [Yildiz, Birol] Gulhane Training & Res Hosp, Dept Med Oncol, Ankara, Turkey. [Kose, Fatih] Baskent Univ, Adana Med Fac, Dept Med Oncol, Adana, Turkey. [Kaplan, Muhammet Ali] Dicle Univ, Med Fac, Dept Med Oncol, Diyarbakir, Turkey. [Gulmez, Ahmet] Inonu Univ, Med Fac, Dept Med Oncol, Malatya, Turkey. [Dogan, Ender] Erciyes Univ, Med Fac, Dept Med Oncol, Kayseri, Turkey. [Kilickap, Saadettin] Hacettepe Univ, Med Fac, Dept Med Oncol, Ankara, Turkey. [Guven, Deniz Can; Gurbuz, Mustafa] Ankara Univ, Med Fac, Dept Med Oncol, Ankara, Turkey. [Ergun, Yakup] Ankara Numune Training & Res Hosp, Dept Med Oncol, Ankara, Turkey. [Karaagac, Mustafa] Necmettin Erbakan Univ, Med Fac, Dept Med Oncol, Konya, Turkey. [Demiray, Atike Gokcen] Pamukkale Univ, Med Fac, Dept Med Oncol, Denizli, Turkey. [Turker, Sema] DiskapiYildir Beyazit Training & Res Hosp, Dept Med Oncol, Ankara, Turkey. [Sakalar, Teoman] Sakarya Univ Training & Res Hosp, Dept Med Oncol, Aksaray, Turkey. [Ozkul, Ozlem] Sakarya Univ Training & Res Hosp, Dept Med Oncol, Sakarya, Turkey. [Telli, Tugba Akin] Marmara Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey. [Sahin, Suleyman] Van Training & Res Hosp, Dept Med Oncol, Van, Turkey. [Bilici, Ahmet] Medipol Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey.

Published
2020

41. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Powles, T. van der Heijden, M.S. Castellano, D. Galsky, M.D. Loriot, Y. Petrylak, D.P. Ogawa, O. Park, S.H. Lee, J.-L. De Giorgi, U. Bögemann, M. Bamias, A. Eigl, B.J. Gurney, H. Mukherjee, S.D. Fradet, Y. Skoneczna, I. Tsiatas, M. Novikov, A. Suárez, C. Fay, A.P. Duran, I. Necchi, A. Wildsmith, S. He, P. Angra, N. Gupta, A.K. Levin, W. Bellmunt, J. van der Heijden, M.S. Lee, J.L. Eigl, B.J. Mukherjee, S.D. Suarez, C. Westgeest, H. Flechon, A. Ou, Y.-C. Park, I. Matveev, V. Pérez-Valderrama, B. Cheng, S. Frank, S. Anido, U. Hamzaj, A. Retz, M. Sridhar, S. Scagliotti, G.V. Voortman, J. Alekseev, B. Alyasova, A. Komyakov, B. Dumez, H. Pavic, M. Kimura, G. Mizokami, A. Osanto, S. Arranz, J.A. Piersma, D. Shin, S.J. Karyakin, O. Delgado, I. Gonzalez, J.L. Pang, S.-T. Tran, A. Lipatov, O. Su, W.-P. Flaig, T. Alva, A. Park Kyong, H. Kopyltsov, E. Almagro, E. Domenech, M. Chang, Y.-H. Sautois, B. Ravaux, A. Aravantinos, G. Georgoulias, V. Mulder, S. Kim, Y.J. Kater, F. Chevreau, C. Tagawa, S. Zalewski, P. Joly, F. Hatiboglu, G. Gianni, L. Morelli, F. Tambaro, R. Hashimoto, Y. Nosov, A. Font, A. Rodriguez-Vida, A.M. Jones, R. Vasudev, N. Srinivas, S. Zhang, J. Gil, T. Finch, D. Grimm, M.-O. Su, Y.-L. Chowdhury, S. Hocking, C. Plas, E. North, S. Jensen, N.V. Theodore, C. Imkamp, F. Peer, A. Kobayashi, T. Sakai, H. Sassa, N. Yoshimura, K. Aarts, M. Ferreira Castro, A. Topuzov, M. Rodriguez, J.F. Vazquez, F.J. Tsai, Y.-C. Crabb, S. Hussain, S. Bendell, J. Gross-Goupil, M. Gwenaelle, G. Berger, R. Statsenko, G. Evans, L. Drakaki, A. Somer, B. Davis, I. Lynam, J. Borges, G. Dettino, A. Fay, A.P. Martins, G. Zucca, L.E. Agerbaek, M. Kalofonos, H. Rosenbaum, E. Enokida, H. Kikukawa, H. Nishimura, K. Tamada, S. Uemura, M. Lopez, Y. Gietema, J. Slojewski, M. Fernandes, I. Smolin, A. Mazhar, D. Kalebasty, A.R. Carthon, B. Loidl, W. Franke, F. Girotto, G. Alimohamed, N. Macfarlane, R. Pappot, H. Niegisch, G. Mavroudis, D. Sella, A. Porta, C. Ebara, S. Nakamura, M. Obara, W. Okuno, N. Shinohara, N. Sugimoto, M. Suzuki, A. Tokuda, N. Uemura, H. Yamaguchi, A. Ramirez, F. Rozanowski, P. Wiechno, P. Keam, B. Kislov, N. Plaksin, D. Cicin, I. Kumar, S. Galsky, M.D. Petrylak, D.P. Rosales, J. Vaishampayan, U. Culine, S. Papandreou, C. Nara, T. Erman, M. Kreiger, L. Janoski, J. Rosa, D. Siqueira, M. Canil, C. Sengelov, L. Tourani, J.-M. Arai, G. Hashine, K. Kawakita, M. Nakaigawa, N. Nomi, H. Shiina, H. Suzuki, H. Yonese, J. Kuri, R. Macedo, E. Rivera, S. Villalobos Prieto, A. Polakiewicz-Gilowska, A. Zaucha, R. Lopes, F. Ponomarev, R. Pomerantz, M. Shariat, S. Luk, C. Lesniewski-Kmak, K.

Abstract

Background: Survival outcomes are poor for patients with metastatic urothelial carcinoma who receive standard, first-line, platinum-based chemotherapy. We assessed the overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab (a CTLA-4 inhibitor), as a first-line treatment for metastatic urothelial carcinoma. Methods: DANUBE is an open-label, randomised, controlled, phase 3 trial in patients with untreated, unresectable, locally advanced or metastatic urothelial carcinoma, conducted at 224 academic research centres, hospitals, and oncology clinics in 23 countries. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0 or 1. We randomly assigned patients (1:1:1) to receive durvalumab monotherapy (1500 mg) administered intravenously every 4 weeks; durvalumab (1500 mg) plus tremelimumab (75 mg) administered intravenously every 4 weeks for up to four doses, followed by durvalumab maintenance (1500 mg) every 4 weeks; or standard-of-care chemotherapy (gemcitabine plus cisplatin or gemcitabine plus carboplatin, depending on cisplatin eligibility) administered intravenously for up to six cycles. Randomisation was done through an interactive voice–web response system, with stratification by cisplatin eligibility, PD-L1 status, and presence or absence of liver metastases, lung metastases, or both. The coprimary endpoints were overall survival compared between the durvalumab monotherapy versus chemotherapy groups in the population of patients with high PD-L1 expression (the high PD-L1 population) and between the durvalumab plus tremelimumab versus chemotherapy groups in the intention-to-treat population (all randomly assigned patients). The study has completed enrolment and the final analysis of overall survival is reported. The trial is registered with ClinicalTrials.gov, NCT02516241, and the EU Clinical Trials Register, EudraCT number 2015-001633-24. Findings: Between Nov 24, 2015, and March 21, 2017, we randomly assigned 1032 patients to receive durvalumab (n=346), durvalumab plus tremelimumab (n=342), or chemotherapy (n=344). At data cutoff (Jan 27, 2020), median follow-up for survival was 41·2 months (IQR 37·9–43·2) for all patients. In the high PD-L1 population, median overall survival was 14·4 months (95% CI 10·4–17·3) in the durvalumab monotherapy group (n=209) versus 12·1 months (10·4–15·0) in the chemotherapy group (n=207; hazard ratio 0·89, 95% CI 0·71–1·11; p=0·30). In the intention-to-treat population, median overall survival was 15·1 months (13·1–18·0) in the durvalumab plus tremelimumab group versus 12·1 months (10·9–14·0) in the chemotherapy group (0·85, 95% CI 0·72–1·02; p=0·075). In the safety population, grade 3 or 4 treatment-related adverse events occurred in 47 (14%) of 345 patients in the durvalumab group, 93 (27%) of 340 patients in the durvalumab plus tremelimumab group, and in 188 (60%) of 313 patients in the chemotherapy group. The most common grade 3 or 4 treatment-related adverse event was increased lipase in the durvalumab group (seven [2%] of 345 patients) and in the durvalumab plus tremelimumab group (16 [5%] of 340 patients), and neutropenia in the chemotherapy group (66 [21%] of 313 patients). Serious treatment-related adverse events occurred in 30 (9%) of 345 patients in the durvalumab group, 78 (23%) of 340 patients in the durvalumab plus tremelimumab group, and 50 (16%) of 313 patients in the chemotherapy group. Deaths due to study drug toxicity were reported in two (1%) patients in the durvalumab group (acute hepatic failure and hepatitis), two (1%) patients in the durvalumab plus tremelimumab group (septic shock and pneumonitis), and one (

Published
2020

42. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)

Author

Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M., Zhang, Q. Y., Rodriguez, J. L. M., Campone, M., Hamilton, E., Sohn, J., Guarneri, V., Okada, M., Boyle, F., Neven, P., Cortes, J., Huober, J., Wardley, A., Tolaney, S. M., Cicin, I., Smith, I. C., Frenzel, M., Headley, D., Wei, R., Antonio, B. S., Hulstijn, M., Cox, J., O'Shaughnessy, J., and Rastogi, P.

Published
2020

43. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Author

Petrylak, D.P. de Wit, R. Chi, K.N. Drakaki, A. Sternberg, C.N. Nishiyama, H. Castellano, D. Hussain, S.A. Fléchon, A. Bamias, A. Yu, E.Y. van der Heijden, M.S. Matsubara, N. Alekseev, B. Necchi, A. Géczi, L. Ou, Y.-C. Coskun, H.S. Su, W.-P. Bedke, J. Gakis, G. Percent, I.J. Lee, J.-L. Tucci, M. Semenov, A. Laestadius, F. Peer, A. Tortora, G. Safina, S. Garcia del Muro, X. Rodriguez-Vida, A. Cicin, I. Harputluoglu, H. Tagawa, S.T. Vaishampayan, U. Aragon-Ching, J.B. Hamid, O. Liepa, A.M. Wijayawardana, S. Russo, F. Walgren, R.A. Zimmermann, A.H. Hozak, R.R. Bell-McGuinn, K.M. Powles, T. Wong, S.-L.S. Tan, T.H. Hovey, E.J. Clay, T.D. Wan Ng, S.S. Rutten, A. Machiels, J.-P. Dumez, H. Cheng, S.Y.-S. Ferrario, C. Sengeloev, L. Jensen, N.V. Thibault, C. Laguerre, B. Joly, F. Culine, S. Becht, C. Niegisch, G. Stöckle, M. Grimm, M.-O. Schwentner, C.A. Schultze-Seemann, W. Kalofonos, H. Mavroudis, D. Papandreou, C. Karavasilis, V. Révész, J. Rosenbaum, E. Leibowitz-Amit, R. Kejzman, D. Sarid, D. Scagliotti, G.V. Bracarda, S. Massari, F. Osawa, T. Miyajima, N. Shinohara, N. Fukuta, F. Ohyama, C. Obara, W. Yamashita, S. Tomita, Y. Kawai, K. Fukasawa, S. Oyama, M. Yonese, J. Nagata, M. Uemura, M. Nishimura, K. Kawakita, M. Tsunemori, H. Hashine, K. Inokuchi, J. Yokomizo, A. Nagamori, S. Lee, H.J. Park, S.H. Rha, S.Y. Kim, Y.J. Lee, Y.-G. Vazquez Cortés, L. Lorena Urzua Flores, C. Blaisse, R.J.B. Erdkamp, F.L.G. Aarts, M.J.B. Wojcik-Tomaszewska, J. Tomczak, P. Sikora-Kupis, B. Schenker, M. Herzal, A.A. Udrea, A.A. Karlov, P. Fomkin, R. Gajate Borau, P. Grande, E. Delgado Mignorance, J.I. Su, Y.-L. Li, J.-R. Lin, C.-L. Lin, C.-C. Yeh, S.-P. Erman, M. Urun, Y. Golovko, Y. Bondarenko, I. Sinielnikov, I. Crabb, S.J. Syndikus, I. Huddart, R. Sundar, S. Chowdhury, S. Sarwar, N. Flaig, T.W. Pan, C.X. Schwarz, J.K. Cultrera, J.L. Acs, P.I. Hainsworth, J.D. Herms, B.T. Lawler, W.E. Lowe, T.E.

Abstract

Background: Ramucirumab—an IgG1 vascular endothelial growth factor receptor 2 antagonist—plus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary endpoint of overall survival results for the RANGE trial. Methods: We did a randomised, double-blind, phase 3 trial in patients with advanced or metastatic urothelial carcinoma who progressed during or after platinum-based chemotherapy. Patients were enrolled from 124 investigative sites (hospitals, clinics, and academic centres) in 23 countries. Previous treatment with one immune checkpoint inhibitor was permitted. Patients were randomly assigned (1:1) using an interactive web response system to receive intravenous ramucirumab 10 mg/kg or placebo 10 mg/kg volume equivalent followed by intravenous docetaxel 75 mg/m2 (60 mg/m2 in Korea, Taiwan, and Japan) on day 1 of a 21-day cycle. Treatment continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met. Randomisation was stratified by geographical region, Eastern Cooperative Oncology Group performance status at baseline, and visceral metastasis. Progression-free survival (the primary endpoint) and overall survival (a key secondary endpoint) were assessed in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT02426125; patient enrolment is complete and the last patient on treatment is being followed up for safety issues. Findings: Between July 20, 2015, and April 4, 2017, 530 patients were randomly allocated to ramucirumab plus docetaxel (n=263) or placebo plus docetaxel (n=267) and comprised the intention-to-treat population. At database lock (March 21, 2018) for the final overall survival analysis, median follow-up was 7·4 months (IQR 3·5–13·9). In our sensitivity analysis of investigator-assessed progression-free survival at the overall survival database lock, median progression-free survival remained significantly improved with ramucirumab compared with placebo (4·1 months [95% CI 3·3–4·8] vs 2·8 months [2·6–2·9]; HR 0·696 [95% CI 0·573–0·845]; p=0·0002). Median overall survival was 9·4 months (95% CI 7·9–11·4) in the ramucirumab group versus 7·9 months (7·0–9·3) in the placebo group (stratified HR 0·887 [95% CI 0·724–1·086]; p=0·25). Grade 3 or worse treatment-related treatment-emergent adverse events in 5% or more of patients and with an incidence more than 2% higher with ramucirumab than with placebo were febrile neutropenia (24 [9%] of 258 patients in the ramucirumab group vs 16 [6%] of 265 patients in the placebo group) and neutropenia (17 [7%] of 258 vs six [2%] of 265). Serious adverse events were similar between groups (112 [43%] of 258 patients in the ramucirumab group vs 107 [40%] of 265 patients in the placebo group). Adverse events related to study treatment and leading to death occurred in eight (3%) patients in the ramucirumab group versus five (2%) patients in the placebo group. Interpretation: Additional follow-up supports that ramucirumab plus docetaxel significantly improves progression-free survival, without a significant improvement in overall survival, for patients with platinum-refractory advanced urothelial carcinoma. Clinically meaningful benefit might be restricted in an unselected population. Funding: Eli Lilly and Company. © 2020 Elsevier Ltd

Published
2020

44. ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3

Author

Selvaggi, G., primary, Wakelee, H.A., additional, Mok, T., additional, Wu, Y.-L., additional, Reck, M., additional, Chiappori, A., additional, Cicin, I., additional, Lee, D.H., additional, Breder, V., additional, Fan, Y., additional, Orlov, S., additional, Poddubskaya, E., additional, Wang, Z., additional, Cheng, Y., additional, Liu, Y., additional, Wu, G., additional, Mao, L., additional, Zhou, J., additional, Oertel, V., additional, Horn, L., additional, and Liang, C., additional

Published
2020
Full Text
View/download PDF

45. P-209 Multicenter real life experience of biological agents in patients with metastatic colorectal cancer

Author

Demirci, U., primary, Ertürk, I., additional, Arslan, Ç., additional, Bilici, A., additional, Çevik, D., additional, Cicin, I., additional, Dane, F., additional, Dölek, B., additional, Kaplan, M., additional, Karadurmuş, N., additional, Kose, F., additional, Şendur, M., additional, Ürün, Y., additional, and Kılıçkap, S., additional

Published
2020
Full Text
View/download PDF

46. Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey

Author

Kilickap, S., Ozturk, A., Karadurmus, N., Korkmaz, T., Yumuk, P., Cicin, I., Paydas, S., Cilbir, E., Sakalar, T., Uysal, M., Uskent, N., Demir, N., Sakin, A., Turhal, N., Keskin, S., Tural, D., Eralp, Y., Basal, F., Hatime Yasar, Sendur, M. A., Demirci, U., Cubukcu, E., Karaagac, M., Karaca, S., Tatli, A., Yetisyigit, T., Urvay, S., Gursoy, P., Uluc, B. Oyan, Turna, Z., Kucukoner, M., Olmez, O., Cabuk, D., Seker, M., Unal, O., Meydan, N., Okutur, S., Tunali, D., Kilickap, S. Hacettepe Univ, Fac Med, Dept Med Oncol, Ankara, Turkey, Ozturk, A. Istanbul Sureyyapasa Chest Dis & Thorac Surg Trai, Istanbul, Turkey, Karadurmus, N. Saglik Bilimleri Univ, Fac Med, Dept Med Oncol, Ankara, Turkey, Korkmaz, T. Acibadem Maslak Hosp, Istanbul, Turkey, Yumuk, P. Marmara Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey, Cicin, I. Trakya Univ, Fac Med, Dept Med Oncol, Edirne, Turkey, Paydas, S. Cukurova Univ, Balcali Hosp, Adana, Turkey, Cilbir, E. Diskapi Yildirim Beyazit Training & Res Hosp, Ankara, Turkey, Sakalar, T. Erciyes Univ, Fac Med, Med Oncol, Kayseri, Turkey, Uysal, M. Afyon Kocatepe Univ, Fac Med, Med Oncol, Afyon, Turkey, Uskent, N., Turhal, N. Anadolu Med Ctr, Kocaeli, Turkey, Demir, N. Sivas Numune Hosp, Sivas, Turkey, Sakin, A. Okmeydani Training & Res Hosp, Istanbul, Turkey, Keskin, S. Mem Sisli Hosp, Istanbul, Turkey, Tural, D. Istanbul Bakirkoy Training & Res Hosp, Med Oncol, Istanbul, Turkey, Eralp, Y. Istanbul Univ, Inst Oncol, Istanbul, Turkey, Basal, F. Ankara Ataturk Chest Dis & Thorac Surg Training &, Ankara, Turkey, Yasar, H. Ankara Univ, Fac Med, Ankara, Turkey, Sendur, M. A. Yildirim Beyazit Univ, Fac Med, Ankara, Turkey, Demirci, U. Saglik Bilimleri Univ, Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Dept Med Oncol, Ankara, Turkey, Cubukcu, E. Bursa Uludag Univ, Fac Med, Bursa, Turkey, Karaagac, M. Necmettin Erbakan Univ, Meram Fac Med, Konya, Turkey, Karaca, S. Ege Univ, Fac Med, Izmir, Turkey, Tatli, A. Akdeniz Univ, Fac Med, Antalya, Turkey, Yetisyigit, T. Namik Kemal Univ Hosp, Med Oncol, Tekirdag, Turkey, Urvay, S. Acibadem Kayseri Hosp, Kayseri, Turkey, Gursoy, P. Izmir Dr Suat Seren Thorac Dis & Surg Training &, Izmir, Turkey, Uluc, B. Oyan Acibadem Altunizade Hosp, Istanbul, Turkey, Turna, Z. Istanbul Univ, Cerrahpasa Fac Med, Istanbul, Turkey, Kucukoner, M. Dicle Univ, Fac Med, Diyarbakir, Turkey, Olmez, O. Medipol Univ Hosp, Istanbul, Turkey, Cabuk, D. Kocaeli Univ, Fac Med, Kocaeli, Turkey, Seker, M. Bayindir Hosp Sogutozu, Ankara, Turkey, Unal, O. Izmir Bozyaka Training & Res Hosp, Izmir, Turkey, Meydan, N. Adnan Menderes Univ, Fac Med, Aydin, Turkey, Okutur, S. Med Pk Bahcelievler Hosp, Istanbul, Turkey, and Tunali, D. Koc Univ, Fac Med, Istanbul, Turkey

Subjects
Crizotinib, NSCLC, ALK Inhibitor
Abstract

WOS: 000454014501235 Background: Increasing evidence leads to a ratiocination that genetic heterogeneity of the lung adenocarcinoma patients with sensitive EGFR mutations may impact clinical responses and outcomes to EGFR-TKIs. Method: We performed targeted NGS with a gene panel covering 416 cancer-related genes to profile genetic characteristics of 69 lung adenocarcinoma patients with activating EGFR mutations and assessed the contribution of targeted NGS to exploration of genetic heterogeneity of such cohort. Result: We detected total 200 actionable genetic alterations (mean 2.9 variations per patient, range: 1-7 variations) in tumor DNA and 140 actionable genetic alterations (mean 2.0 variations per patient, range: 0-5 variations) in matched plasma ctDNA, respectively. The concurrent genes with the highest mutation rate were TP53 (observed in 72.5% patients), other uncommon EGFR mutations (observed in 21.7% patients), EGFR amplification (observed in 20.3% patients), RB1 (observed in 10.1% patients), PIK3CA (observed in 7.2% patients), and MYC (observed in 5.8% patients). NGS provides EGFR mutation detection in plasma with a test sensitivity of 88.2% and specificity of 100.0%.

Published
2018

47. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Author

Burtness, B. Harrington, K.J. Greil, R. Soulières, D. Tahara, M. de Castro, G., Jr Psyrri, A. Basté, N. Neupane, P. Bratland, Å. Fuereder, T. Hughes, B.G.M. Mesía, R. Ngamphaiboon, N. Rordorf, T. Wan Ishak, W.Z. Hong, R.-L. González Mendoza, R. Roy, A. Zhang, Y. Gumuscu, B. Cheng, J.D. Jin, F. Rischin, D. Lerzo, G. Tatangelo, M. Varela, M. Zarba, J.J. Boyer, M. Gan, H. Gao, B. Hughes, B. Mallesara, G. Taylor, A. Burian, M. Barrios, C.H. de Castro Junior, D.O. Castro, G. Franke, F.A. Girotto, G. Lima, I.P.F. Nicolau, U.R. Pinto, G.D.J. Santos, L. Victorino, A.-P. Chua, N. Couture, F. Gregg, R. Hansen, A. Hilton, J. McCarthy, J. Soulieres, D. Ascui, R. Gonzalez, P. Villanueva, L. Torregroza, M. Zambrano, A. Holeckova, P. Kral, Z. Melichar, B. Prausova, J. Vosmik, M. Andersen, M. Gyldenkerne, N. Jurgens, H. Putnik, K. Reinikainen, P. Gruenwald, V. Laban, S. Aravantinos, G. Boukovinas, I. Georgoulias, V. Kwong, D. Al-Farhat, Y. Csoszi, T. Erfan, J. Horvai, G. Landherr, L. Remenar, E. Ruzsa, A. Szota, J. Billan, S. Gluck, I. Gutfeld, O. Popovtzer, A. Benasso, M. Bui, S. Ferrari, V. Licitra, L. Nole, F. Fujii, T. Fujimoto, Y. Hanai, N. Hara, H. Matsumoto, K. Mitsugi, K. Monden, N. Nakayama, M. Okami, K. Oridate, N. Shiga, K. Shimizu, Y. Sugasawa, M. Takahashi, M. Takahashi, S. Tanaka, K. Ueda, T. Yamaguchi, H. Yamazaki, T. Yasumatsu, R. Yokota, T. Yoshizaki, T. Kudaba, I. Stara, Z. Cheah, S.K. Aguilar Ponce, J. Gonzalez Mendoza, R. Hernandez Hernandez, C. Medina Soto, F. Buter, J. Hoeben, A. Oosting, S. Suijkerbuijk, K. Bratland, A. Brydoey, M. Alvarez, R. Mas, L. Caguioa, P. Querol, J. Regala, E.E. Tamayo, M.B. Villegas, E.M. Kawecki, A. Karpenko, A. Klochikhin, A. Smolin, A. Zarubenkov, O. Goh, B.C. Cohen, G. du Toit, J. Jordaan, C. Landers, G. Ruff, P. Szpak, W. Tabane, N. Brana, I. Iglesias Docampo, L. Lavernia, J. Mesia, R. Abel, E. Muratidu, V. Nielsen, N. Cristina, V. Rothschild, S. Wang, H.-M. Yang, M.-H. Yeh, S.-P. Yen, C.-J. Soparattanapaisarn, N. Sriuranpong, V. Aksoy, S. Cicin, I. Ekenel, M. Harputluoglu, H. Ozyilkan, O. Agarwala, S. Ali, H. Alter, R. Anderson, D. Bruce, J. Campbell, N. Conde, M. Deeken, J. Edenfield, W. Feldman, L. Gaughan, E. Goueli, B. Halmos, B. Hegde, U. Hunis, B. Jotte, R. Karnad, A. Khan, S. Laudi, N. Laux, D. Martincic, D. McCune, S. McGaughey, D. Misiukiewicz, K. Mulford, D. Nadler, E. Nunnink, J. Ohr, J. O'Malley, M. Patson, B. Paul, D. Popa, E. Powell, S. Redman, R. Rella, V. Rocha Lima, C. Sivapiragasam, A. Su, Y. Sukari, A. Wong, S. Yilmaz, E. Yorio, J.

Abstract

Background: Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response. Methods: KEYNOTE-048 was a randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries. Participants were stratified by PD-L1 expression, p16 status, and performance status and randomly allocated (1:1:1) to pembrolizumab alone, pembrolizumab plus a platinum and 5-fluorouracil (pembrolizumab with chemotherapy), or cetuximab plus a platinum and 5-fluorouracil (cetuximab with chemotherapy). Investigators and participants were aware of treatment assignment. Investigators, participants, and representatives of the sponsor were masked to the PD-L1 combined positive score (CPS) results; PD-L1 positivity was not required for study entry. The primary endpoints were overall survival (time from randomisation to death from any cause) and progression-free survival (time from randomisation to radiographically confirmed disease progression or death from any cause, whichever came first) in the intention-to-treat population (all participants randomly allocated to a treatment group). There were 14 primary hypotheses: superiority of pembrolizumab alone and of pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival and progression-free survival in the PD-L1 CPS of 20 or more, CPS of 1 or more, and total populations and non-inferiority (non-inferiority margin: 1·2) of pembrolizumab alone and pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival in the total population. The definitive findings for each hypothesis were obtained when statistical testing was completed for that hypothesis; this occurred at the second interim analysis for 11 hypotheses and at final analysis for three hypotheses. Safety was assessed in the as-treated population (all participants who received at least one dose of allocated treatment). This study is registered at ClinicalTrials.gov, number NCT02358031. Findings: Between April 20, 2015, and Jan 17, 2017, 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab with chemotherapy (n=300); of these, 754 (85%) had CPS of 1 or more and 381 (43%) had CPS of 20 or more. At the second interim analysis, pembrolizumab alone improved overall survival versus cetuximab with chemotherapy in the CPS of 20 or more population (median 14·9 months vs 10·7 months, hazard ratio [HR] 0·61 [95% CI 0·45–0·83], p=0·0007) and CPS of 1 or more population (12·3 vs 10·3, 0·78 [0·64–0·96], p=0·0086) and was non-inferior in the total population (11·6 vs 10·7, 0·85 [0·71–1·03]). Pembrolizumab with chemotherapy improved overall survival versus cetuximab with chemotherapy in the total population (13·0 months vs 10·7 months, HR 0·77 [95% CI 0·63–0·93], p=0·0034) at the second interim analysis and in the CPS of 20 or more population (14·7 vs 11·0, 0·60 [0·45–0·82], p=0·0004) and CPS of 1 or more population (13·6 vs 10·4, 0·65 [0·53–0·80], p

Published
2019

48. metastatic, trastuzumab-naive breast cancer: real-life practice outcomes

Author

Esin, E, Oksuzoglu, B, Bilici, A, Cicin, I, Kostek, O, Kaplan, MA, Aksoy, S, Aktas, BY, Ozdemir, O, Alacacioglu, A, Cabuk, D, Sumbul, AT, Sakin, A, Paydas, S, Yetisir, E, Er, O, Korkmaz, T, Yildirim, N, Sakalar, T, Demir, H, Artac, M, Karaagac, M, Harputluoglu, H, Bilen, E, Erdur, E, Degirmencioglu, S, Aliyev, A, Cil, T, Olgun, P, Basaran, G, Gumusay, O, Demir, A, Tanrikulu, E, Yumuk, PF, Imamoglu, I, Oyan, B, Cetin, B, Haksoyler, V, Karadurmus, N, Erturk, I, Evrensel, T, Yilmaz, H, Beypinar, I, Kocer, M, Pilanci, KN, Seker, M, Urun, Y, Eren, T, and Demirci, U

Subjects
Pertuzumab, Trastuzumab, AntiHER2, Visceral metastasis, Brain metastasis
Abstract

PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers.ResultsMedian age was 51 (22-82). Median PFS was 28.5months, while median OS was 40.3months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8m vs. 28.5m; p=0.002) and OS (26.7m vs. 40.3m; p=0.009). Patients older than 65years of age (n: 42, 13.2%) had significantly lower OS results (19.8m vs. 40.3m; p=0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure.ConclusionsOur RLP trial included only visceral metastatic, trastuzumab-naive BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date. C1 [Esin, Ece; Oksuzoglu, B.; Erdur, E.; Demirci, U.] Univ Hlth Sci, Dept Med Oncol, Dr AY Ankara Oncol Educ & Res Hosp, Ankara, Turkey. [Bilici, A.] Medipol Univ, Int Hlth Ctr, Dept Med Oncol, Istanbul, Turkey. [Cicin, I.; Kostek, O.] Trakya Univ, Dept Med Oncol, Edirne, Turkey. [Kaplan, M. A.] Dicle Univ, Dept Med Oncol, Fac Med, Diyarbakir, Turkey. [Aksoy, S.; Aktas, B. Y.] Hacettepe Univ, Dept Med Oncol, Fac Med, Ankara, Turkey. [Ozdemir, O.; Alacacioglu, A.] Izmir KC Univ, Ataturk Educ & Res Hosp, Dept Med Oncol, Izmir, Turkey. [Cabuk, D.] Kocaeli Univ, Fac Med, Dept Med Oncol, Izmit, Turkey. [Sumbul, A. T.] Baskent Univ, Dept Med Oncol, Adana Hosp, Adana, Turkey. [Sakin, A.] Istanbul Okmeydani Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey. [Paydas, S.; Yetisir, E.] Cukurova Univ, Dept Med Oncol, Fac Med, Adana, Turkey. [Er, O.; Basaran, G.] Acibadem MAA Univ, Acibadem Maslak Hosp, Dept Med Oncol, Istanbul, Turkey. [Korkmaz, T.; Oyan, B.] Acibadem MAA Univ, Acibadem Altunizade Hosp, Dept Med Oncol, Istanbul, Turkey. [Yildirim, N.] Dr Ersin Arslan Training & Res Hosp, Dept Med Oncol, Gaziantep, Turkey. [Sakalar, T.] Erciyes Univ, Dept Med Oncol, Fac Med, Kayseri, Turkey. [Demir, H.] Kayseri Educ & Res Hosp, Univ Hlth Sci, Dept Med Oncol, Kayseri, Turkey. [Artac, M.; Karaagac, M.] Necmettin Erbakan Univ, Meram Med Fac, Dept Med Oncol, Konya, Turkey. [Harputluoglu, H.; Bilen, E.] Inonu Univ, Dept Med Oncol, Turgut Ozal Med Ctr, Malatya, Turkey. [Degirmencioglu, S.] Pamukkale Univ, Dept Med Oncol, Fac Med, Denizli, Turkey. [Aliyev, A.] Bezmialem Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey. [Cil, T.; Olgun, P.] Adana City Hosp, Univ Hlth Sci, Dept Med Oncol, Adana, Turkey. [Gumusay, O.] Gaziosmanpasa Univ, Dept Med Oncol, Fac Med, Tokat, Turkey. [Demir, A.] Univ Hlth Sci, Dept Med Oncol, Istanbul Okmeydani Educ & Res Hosp, Istanbul, Turkey. [Tanrikulu, E.; Yumuk, P. F.] Marmara Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey. [Imamoglu, Inanc] Univ Hlth Sci, Ankara Diskapi Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey. [Cetin, B.] RTE Univ, Dept Med Oncol, Fac Med, Rize, Turkey. [Haksoyler, V.] Univ Hlth Sci, Diyarbakir GY Educ & Res Hosp, Dept Med Oncol, Diyarbakir, Turkey. [Karadurmus, N.; Erturk, I.] Univ Hlth Sci, Gulhane Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey. [Evrensel, T.; Yilmaz, H.] Uludag Univ, Dept Med Oncol, Fac Med, Bursa, Turkey. [Beypinar, I.] Afyon Kocatepe Univ, Dept Med Oncol, Fac Med, Afyon, Turkey. [Kocer, M.] Isparta SD Univ, Dept Med Oncol, Fac Med, Isparta, Turkey. [Pilanci, K. N.] Univ Hlth Sci, Dept Med Oncol, Haseki Educ & Res Hosp, Istanbul, Turkey. [Seker, M.; Urun, Y.] Ankara Bayindir Hosp, Dept Med Oncol, Ankara, Turkey. [Urun, Y.] Ankara Univ, Dept Med Oncol, Fac Med, Ankara, Turkey. [Yildirim, N.; Eren, T.] Univ Hlth Sci, Numune Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey.

Published
2019

49. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

Author

Esin, E., Oksuzoglu, B., Bilici, A., Cicin, I., Kostek, O., Kaplan, M.A., Aksoy, S., Aktas, B.Y., Ozdemir, O., Alacacioglu, A., Cabuk, D., Sumbul, A.T., Sakin, A., Paydas, S., Yetisir, E., Er, O., Korkmaz, T., Yildirim, N., Sakalar, T., Demir, H., Artac, M., Karaagac, M., Harputluoglu, H., Bilen, E., Erdur, E., Değirmencioğlu, Serkan, Aliyev, A., Cil, T., Olgun, P., Basaran, G., Gumusay, O., Demir, A., Tanrikulu, E., Yumuk, P.F., Imamoglu, I., Oyan, B., Cetin, B., Haksoyler, V., Karadurmus, N., Erturk, I., Evrensel, T., Yilmaz, H., Beypinar, I., Kocer, M., Pilanci, K.N., Seker, M., Urun, Y., Eren, T., Demirci, U., Uluc Oyan, B., Beypinar, Kocer, and Turkish Oncology Group

Subjects
vomiting, loading drug dose, myalgia, peripheral neuropathy, retrospective study, very elderly, diarrhea, clinical outcome, thrombocytopenia, rash, Docetaxel, AntiHER2, paclitaxel, middle aged, Antineoplastic Combined Chemotherapy Protocols, brain metastasis, Neoplasm Metastasis, Practice Patterns, Physicians', cancer survival, Visceral metastasis, antineoplastic agent, Aged, 80 and over, progression free survival, breast tumor, adult, lung metastasis, Carcinoma, Ductal, Breast, Prognosis, clinical practice, Survival Rate, trastuzumab, aged, female, priority journal, Paget nipple disease, young adult, mucosa inflammation, blood transfusion reaction, hyperbilirubinemia, side effect, overall survival, lobular carcinoma, Breast Neoplasms, Antibodies, Monoclonal, Humanized, cancer prognosis, Article, multiple cycle treatment, transthoracic echocardiography, pertuzumab, cancer combination chemotherapy, hypokalemia, neutropenia, follow up, metastasis, Humans, Neoplasm Invasiveness, human, arthralgia, human epidermal growth factor receptor 2 positive breast cancer, Retrospective Studies, hypertransaminasemia, tumor invasion, major clinical study, mortality, liver metastasis, Carcinoma, Lobular, monoclonal antibody, epidermal growth factor receptor 2, fatigue, pathology, heart left ventricle ejection fraction, Follow-Up Studies
Abstract

Purpose: In this study, we aimed to describe the real-life practice outcomes of pertuzumab–trastuzumab–taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients. Methods: This study was conducted by Turkish Oncology Group and included 317 patients’ data from 36 centers. Results: Median age was 51 (22–82). Median PFS was 28.5 months, while median OS was 40.3 months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8 m vs. 28.5 m; p = 0.002) and OS (26.7 m vs. 40.3 m; p = 0.009). Patients older than 65 years of age (n: 42, 13.2%) had significantly lower OS results (19.8 m vs. 40.3 m; p = 0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5–40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure. Conclusions: Our RLP trial included only visceral metastatic, trastuzumab-naïve BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab–trastuzumab–taxane therapy to date. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.

Published
2019

50. Effectiveness and Safety of LMWH Treatment in Patients With Cancer

Author

Ozaslan, E, Ozkan, M, Cicin, I, Benekli, M, Kocer, M, Uysal, M, Oksuzoglu, B, Isikdogan, A, Cubukcu, E, Elkiran, ET, Dane, F, Aliustaoglu, M, Sevinc, A, Karaoglu, A, Ulas, A, and Gokoz-Dogu, G

Subjects
LMWH, VTE, bemiparin, enoxaparin, thrombosis, cancer
Abstract

We compared the efficacy and safety of low-molecular-weight heparins (LMWHs) in patients with cancer who are at low risk of venous thromboembolism (VTE). Patients were treated by medical oncologists in Turkey at 15 sites, where they were enrolled and followed up for a period of 12 months. Due to the study design, there was no specific treatment protocol for LMWH. Primary end points were efficacy and the time to change in VTE status. Of the included 250 patients, 239 (95.6%), 176 (70.4%), 130 (52.0%), and 91 (36.4%) completed their day 15, month 3, month 6, and month 12 visits, respectively. Number of patients treated with enoxaparin, bemiparin, and tinzaparin were 133, 112, and 5, respectively. Anticoagulant therapy provoked thrombus resolution in 1.2% and 12.7% of patients using enoxaparin and bemiparin, respectively (P = .004). Thrombus resolution was observed in 81 more patients at month 3 visit. This ratio was 35 (40.2%) of 87 and 46 (54.1%) of 85 patients administered enoxaparin and bemiparin at the third visit, respectively (P = .038). Thrombus resolution was observed in 21 more patients during month 6 visit. This ratio was 5 (7.7%) of 65 and 15 (23.4%) of 64 patients administered enoxaparin and bemiparin at the fourth visit, respectively (P = .022). The LMWH was discontinued in only 2 patients due to gastrointestinal bleeding. This pioneering study shows bemiparin is more effective than enoxaparin in thrombosis resolution and has a similar tolerability profile.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results